Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.

Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit writes about the critical federal funding at risk and what this ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Researchers have identified a range of genetic alterations that may lead to resistance to KRAS G12C inhibitors in patients ...

Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a major milestone in the company’s transition ...

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ANOC-001 in Advanced ...

Cell line-specific efficacy profiles: SIL204 showed robust activity across multiple pancreatic cancer cell lines with ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including ... designed to inhibit multiple RAS mutations, so if the cancer mutates, and another type of ...